GLP-1 Medications and Obesity-Related Cancer Risk: What Researchers Are Learning


Obesity is associated with an increased risk of several cancers, including endometrial cancer. As GLP-1 receptor agonists become more widely used for weight management, researchers are beginning to examine whether their effects may extend to the risk of developing obesity-related cancers.
A recent observational study compared cancer incidence among adults with obesity but without diabetes who used GLP-1RAs and those who received diet or exercise counseling. Bram Goldstein, Ph.D., President and Senior Clinical Fellow of the Women’s Cancer Research Foundation, provides clinical context on the findings.
As obesity rates continue to rise, so, too, have deaths from obesity-related cancers, such as uterine and colon cancer, with age-adjusted mortality rates tripling between 1999 and 2020.
A new study from Annals of Oncology examined the association between developing an obesity-related cancer and glucagon-like peptide-1 receptor agonists (GLP-1RAs) use in obese people without diabetes. The trial compared people who received two or more prescriptions of a GLP-1RA with people who received diet or exercise counselling to manage their weight. The incidence of obesity-related cancers was monitored for two years.
The study reported that among GLP-1RA users, a 58% reduction was found in the incidence of endometrial cancer, which is the most common gynecologic cancer and very closely linked to obesity. The risk of developing any of 13 obesity-associated cancers was 41% lower in people taking GLP-1RAs compared to people managing their obesity with diet and exercise alone.
Weight loss probably played a key role in the association between GLP-1RA use and reduced cancer risk by improving metabolic health; however, several strands of evidence suggest that anti-cancer effects of GLP-1RAs may extend beyond their direct impacts on obesity. For example, GLP-1RAs are reportedly present on cells of obesity-related cancers such as endometrial cancer, indicative of a biologically plausible anti-cancer effect.
Exploratory analyses of subgroups in the study found that the association between weight-loss drugs and a reduction in cancer risk for men was nearly 70%, much higher than for women. Women have a harder time staying on GLP-1RA medication due to a higher prevalence of gastrointestinal side effects from the drugs, which may explain the difference.
Why This Cancer Research Matters
The relationship between obesity, metabolic health, and cancer risk is complex. Research examining GLP-1RAs may help scientists better understand whether these medications could influence the development of obesity-associated cancers, including endometrial cancer.
These findings show an association; they do not establish that GLP-1RAs prevent cancer. Because the study was observational and examined short-term cancer incidence over two years, longer-term research is needed to better understand the relationship and determine whether any effects extend beyond weight loss.
Read the original article: Weight-loss drugs linked to lower cancer risk in obese people without diabetes | Nature Research Custom
Medical note: This article is intended for educational purposes only and does not provide medical advice, diagnosis, or individualized screening or treatment recommendations. Please consult a qualified healthcare professional about personal health concerns.



Comments